Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: Clinical implications

Journal of Clinical Oncology

Volumn 23, Issue 9, 2005, Pages 1951-1961

  Taghian, Alphonse G ^a   Abi Raad, Rita ^a   Assaad, Sherif I ^a   Casty, Adrian ^a   Ancukiewicz, Marek ^a   Yeh, Eren ^a   Molokhia, Peryhan ^a   Attia, Khaled ^a   Sullivan, Timothy ^a   Kuter, Irene ^a   Boucher, Yves ^a   Powell, Simon N ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OXYGEN TENSION; OXYGENATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TISSUE PRESSURE; TREATMENT RESPONSE; TUMOR VOLUME; ULTRASOUND; BREAST TUMOR; DRUG ADMINISTRATION; EXTRACELLULAR FLUID; MENOPAUSE; MIDDLE AGED; OXYGEN CONSUMPTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EXTRACELLULAR FLUID; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; OXYGEN CONSUMPTION; PACLITAXEL;

EID: 20144373280     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.119     Document Type: Article

References (41)

1. Bonadonna G, Valagussa P: Primary chemotherapy in operable breast cancer. Semin Oncol 23:464-474, 1996
2. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
3. Kuerer H, Newman L, Smith T, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
4. Boucher Y, Leunig M, Jain RK: Tumor angiogenesis and interstitial hypertension. Cancer Res 56:4264-4266, 1996
5. Jain R, Baxter L: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 48:7022-7032, 1988
6. Netti PA, Roberge S, Boucher Y, et al: Effect of transvascular fluid exchange on pressure-flow relationship in tumors: A proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 52:27-46, 1996
7. Mollica F, Jain RK, Netti PA: A model for temporal heterogeneities of tumor blood flow. Microvasc Res 65:56-60, 2003
8. Griffon-Etienne G, Boucher Y, Brekken C, et al: Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications. Cancer Res 59:3776-3782, 1999
9. Hockel M, Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-276, 2001
10. Teicher B, Lazo J, Sartorelli A: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41:73-81, 1981
11. Teicher B, Holden S, Al-Achi A, et al: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in FSaIIC murine fibrosarcoma. Cancer Res 50: 3339-3344, 1990
12. Coleman C: Hypoxia in tumors: A paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst 80:310-317, 1988
13. Milas L, Hunter N, Mason K, et al: Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55:3564-3568, 1995
14. Roh H, Boucher Y, Kalnicki S, et al: Interstitial hypertension in carcinoma of uterine cervix in patients: Possible correlation with tumor oxygenation and radiation response. Cancer Res 51:6695-6698, 1991
15. Griffon-Etienne G, Boucher Y, Jain RK, et al: Effects of needle insertion in tumors on interstitial fluid pressure. Microvasc Res 54:174-177, 1997
16. Vaupel P, Schlenger K, Knoop C, et al: Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51:3316-3322, 1991
17. Mehta CR, Patel NR, Tsiatis AA: Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 40:819-825, 1984
18. Beyer WH: CRC Standard Mathematical Tables. Boca Raton, FL, CRC Press, 1987
19. Powles T, Hickish T, Makris A, et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547-552, 1995
20. Perez E: Doxorubicin and paclitaxel in the treatment of advanced breast cancer: Efficacy and cardiac considerations. Cancer Invest 19: 155-164, 2001
21. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
22. 21A. Kristjansen P, Boucher Y, Jain R: Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res 53:4764-1766, 1993
23. Boucher Y, Jain R: Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse. Cancer Res 52:5110-5114, 1992
24. Stohrer M, Boucher Y, Stangassinger M, et al: Oncotic pressure in solid tumors is elevated. Cancer Res 60:4251-4255, 2000
25. Padera T, Stoll B, Tooredman J, et al: Pathology: Cancer cells compress intratumour vessels. Nature 427:695, 2004
26. Dunst JHG, Lautenschlager C, Fuchsel G, et al: Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/ Interferon. Int J Radiat Oncol Biol Phys 43:367-373, 1999
27. Myoung H, Hong S-D, Kim Y-Y, et al: Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 163:191-200, 2001
28. Yuan F, Chen Y, Dellian M, et al: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93:14765-14770, 1996
29. Lee CG, Heijn M, di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565-5570, 2000
30. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
31. Minko T, Kopeckova P, Pozharov V, et al: The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm Res 17:505-514, 2000
32. Secomb TW, Hsu R, Ong ET, et al: Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 34: 313-316, 1995
33. Hayakawa K, Hasegawa M, Kawashima M, et al: Comparison of effects of doxorubicin and radiation on p53-dependent apoptosis in vivo. Oncol Rep 7:267-270, 2000
34. Stearns V, Singh B, Tsangaris T, et al: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9:124-133, 2003
35. Durand R, LePard NE: Tumour blood flow influences combined radiation and doxorubicin treatments. Radiother Oncol 42:171-179, 1997
36. Durand R, Aquino-Parsons C: Non-constant tumour blood flow: Implications for therapy. Acta Oncol 40:862-869, 2001
37. Milosevic M, Fyles A, Hedley D, et al: Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 61:6400-6405, 2001
38. Milosevic M, Fyles A, Hedley D, et al: The human tumor microenvironment: Invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 14:249-258, 2004
39. Pietras K, Ostman A, Sjoquist M, et al: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929-2934, 2001
40. Lee I, Boucher Y, Demhartner T, et al: Changes in tumor blood flow, oxygenation and interstitial fluid pressure induced by pentoxyfylline. Br J Cancer 69:492-496, 1994
41. Rubin K, Sjoquist M, Gustafsson AM, et al: Lowering of tumoral interstitial fluid pressure by prostaglandin E1 is paralleled by an increased uptake of 51Cr-EDTA. Int J Cancer 86:636-643, 2000